endbraincancer®
Chris Elliott Fund
Fueling Research & Clinical Trial Enrollment

# Partnering

## for increased patient access, treatment options & impact

*"Together, we can accelerate education, access, and hope for patients with brain cancer."*

~ Dellann Elliott Mydland, President & CEO

## EBCI



425-785-8489 | https://endbraincancer.org | Redmond, Washington

endbraincancer®
Chris Elliott Fund
Fueling Research & Clinical Trial Enrollment

# Who We Are

The End Brain Cancer Initiative (EBCI) is a 501(c)(3) nonprofit dedicated to breaking down barriers to care and increasing patient access to advanced diagnostics, clinical trials, and innovative treatments. For over 23 years, our work has connected thousands of patients and caregivers directly to specialists, devices, diagnostics, treatment centers, and emerging trials through our DIRECT CONNECT patient navigation program — always at no cost to the patient.

## Partnership Mission & Program Team

**Susan Kellner**
Global Digital Outreach & Education

**Shreya Prakash**
Clinical Research & Patient Navigator

**Elise Fyhrie**
Outreach & Mobile App Manager, EBCI

**Ted Lyszczarz**
Video Editor & Producer

## Our Process

### Patient Education & Awareness Campaigns

Nationally distributed digital, print, and social media initiatives focused on treatment options, trials, and biomarkers.

### Clinical Trial Patient Navigation

One-on-one patient and caregiver engagement to pre-qualify, screen, and directly connect individuals with study coordinators — limiting hand-offs and accelerating enrollment.

### Protocol Development Support

Advocacy partnerships increase trust and awareness with both patients and investors.

### Above Brand Sponsorship Opportunities

Support disease education and navigation programs that reach the brain tumor community broadly while aligning your company with trusted patient advocacy.

endbraincancer®
Chris Elliott Fund
Fueling Research & Clinical Trial Enrollment

## Why Partner with EBCI?

**Direct Access to Patients**
We maintain trusted, ongoing communication with patients & care partners eager for new treatment & diagnostic options.

**Patient Voice Integration**
Our insights help design more inclusive protocols and reduce trial barriers.

**Credibility and Reach**
Advocacy partnerships increase trust and awareness with both patients and industry partners/stakeholders.

**Accelerated Enrollment**
Our process reduces the large gap that exists related to educating and getting patients into advanced treatments, diagnostics and clinical trials, while reducing delays between patient education/interest, screening, and investigator/clinical trial coordinator contacts.

**Demonstrated Results**
In 2024, EBCI sourced over 400 qualified patients for GBM/rGBM trials.

endbraincancer®
Chris Elliott Fund
Fueling Research & Clinical Trial Enrollment

# Driving Impact Through Partnership

We collaborate with biopharma, healthcare providers, principal investigators, biotech/biomed, diagnostics, and device companies — primarily in the pre-approval space — to accelerate education, engagement, and patient access. Our partners include EXVADE, IMVAX, Ono Pharmaceuticals, Deciphera, Agios, Servier, and Novocure, among others. EBCI develops and executes broad & targeted disease education, outreach, and patient awareness campaigns that naturally increase clinical trial enrollment — not through marketing, but through 1:1 patient engagement, trust and advocacy.

### *Patient Education & Awareness Campaigns*

Nationally distributed digital, print, and social media initiatives focused on treatment options, trials, and biomarkers.

### *Clinical Trial Patient Navigation*

One-on-one patient and caregiver engagement to pre-qualify, screen, and directly connect individuals with study coordinators — limiting hand-offs and accelerating enrollment.

### *Protocol Development Support*

Guidance for including the patient voice and removing access barriers within trial design.

### *Above Brand Sponsorship Opportunities*

Support disease education and navigation programs that reach the brain tumor community broadly while aligning your company with trusted patient advocacy.


Dellann Elliott Mydland

https://EndBrainCancer.org

dellann@endbraincancer.org

425-785-8489



endbraincancer®
Chris Elliott Fund
Fueling Research & Clinical Trial Enrollment